Bispecific agents: the future of AML and MDS treatment?
The pivotal ZUMA-1 trial for NHL
Which CLL patients would benefit from intensive therapy?
How durable are the responses of CLL patients to therapy?
Overcoming the shortfalls of ibrutinib with fludarabine in CLL patientss